ArticleChinese medical journal2026
Efficacy and toxicity of maintenance therapy with PD-1/PD-L1 inhibitors plus pemetrexed vs . immunotherapy alone for stage III/IV non-squamous non-small cell lung cancer: A real-world study.
Article in Chinese medical journal, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
17 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundIt is a common challenge in clinical decision-making to optimize and select maintenance therapy (MT) regimens that balance efficacy and toxicity. This study compares the efficacy and toxicity of immune checkpoint inhibitors (ICIs) monotherapy vs . ICIs plus pemetrexed as MT following initial immunotherapy in non-small cell lung cancer (NSCLC) patients.
methodsWe performed a multicenter retrospective real-world study that included non-squamous NSCLC (nqNSCLC) patients who received 4-6 cycles of ICIs plus pemetrexed as the first-line treatment and continued ICIs monotherapy or ICIs plus pemetrexed as MT between April 1, 2018, and June 30, 2023. Progression-free survival (PFS) and overall survival (OS) were reported using the Kaplan-Meier method. Adverse events (AEs) were evaluated according to the Common Terminology Criteria for Adverse Events (CTCAE) version 5.0.
resultsOut of 1060 recorded patients, 328 met the inclusion criteria for the analysis: 235 received ICIs plus pemetrexed, and 93 received ICIs monotherapy as MT. Demographic characteristics were comparable between the two groups. No significant difference was observed in median PFS (15.0 vs . 14.6 months; P = 0.756) between the two groups, regardless of programmed death-ligand 1 (PD-L1) stratification. Similarly, median OS did not differ significantly (28.3 vs . 38.9 months; P = 0.799). Anemia incidence was higher in the ICIs plus pemetrexed MT group (48.5 vs . 32.3%). Patients who were rechallenged with ICIs as second-line therapy experienced improved OS compared to those who received non-ICI therapy (not reached vs . 20.4 months; P = 0.009).
conclusionThe absence of statistically significant survival difference and increased toxicity in the ICIs plus pemetrexed cohort suggest that chemotherapy may not be crucial in MT. Moreover, the significant benefits of ICIs-based therapy as a second-line treatment reinforce its value, offering confidence to both patients and physicians in making informed decisions regarding MT strategies and subsequent systemic therapies.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.